Insight Molecular Diagnostics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Insight Molecular Diagnostics Inc. (IMDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.37% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-10
- Insight Molecular Diagnostics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 0.00%, a 100.00% decline year-over-year.
- Insight Molecular Diagnostics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.15%.
- Insight Molecular Diagnostics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.72%, a 69.86% increase year-over-year.
- Insight Molecular Diagnostics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 2.19%, a 114.71% increase year-over-year.
- Insight Molecular Diagnostics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.83%, a 11.14% decline from fiscal 2024.
- Insight Molecular Diagnostics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.31%, a 8.02% increase from fiscal 2023.
- Insight Molecular Diagnostics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.99%, a 64.20% increase from fiscal 2022.
- Insight Molecular Diagnostics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.43%, a 138.24% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 4.37% 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | 3.83% 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | 3.84% 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | 4.15% 10-Q · filed 2026-08-10 | ||||
| 2025-03-31 | 4.15% 10-Q · filed 2026-05-13 | ||||
| 2024-12-31 | 4.31% 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | 4.45% 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | 4.45% 10-Q · filed 2025-08-11 | ||||
| 2023-12-31 | 3.99% 10-K · filed 2025-03-24 | ||||
| 2023-09-30 | 3.76% 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | 3.76% 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | 3.72% 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | 2.43% 10-K · filed 2024-04-16 | ||||
| 2022-09-30 | 2.29% 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | 2.24% 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 2.19% 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | 1.02% 10-K · filed 2023-04-12 | ||||
| 2021-09-30 | 0.99% 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | 0.88% 10-Q · filed 2022-08-12 | ||||
| 2021-03-31 | 1.02% 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | 1.08% 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | 1.14% 10-Q · filed 2021-11-09 | ||||
| 2020-06-30 | 1.20% 10-Q · filed 2021-08-11 | ||||
| 2020-03-31 | 1.34% 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | 2.05% 10-K · filed 2021-03-19 | ||||
| 2019-09-30 | 2.10% 10-Q · filed 2020-11-12 | ||||
| 2019-06-30 | 2.42% 10-Q · filed 2020-07-29 | ||||
| 2019-03-31 | 2.47% 10-Q · filed 2020-05-12 | ||||
| 2018-12-31 | 2.85% 10-K · filed 2020-03-26 | ||||
| 2018-09-30 | 2.84% 10-Q · filed 2018-11-13 | 2.93% 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | 2.97% 10-Q · filed 2019-08-14 | ||||
| 2018-03-31 | 2.88% 10-Q · filed 2019-05-14 | 2.81% 10-Q · filed 2018-05-15 | |||
| 2017-12-31 | 2.03% 10-K · filed 2019-04-01 | ||||
| 2017-09-30 | 1.83% 10-Q · filed 2018-11-13 | 2.00% 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | 1.79% 10-Q · filed 2018-08-14 | ||||
| 2017-03-31 | 2.11% 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |